Masterclass Program




This one-day Masterclass (capped at 60 registrants) follows on from a one-day conference Mental Health, Medicinal Cannabis and Nutritional Medicine, and is focused on learning how to prescribe medicinal cannabis for common mental health conditions and chronic pain. Case studies cover anxiety, PTSD, sleep disorders, depression and co-morbid pain. The Masterclass helps prepare applicants with the knowledge to apply through the TGA’s Special Access Scheme-B and the Authorised Prescriber Scheme. It features experts in medicinal cannabis from the US Dr Ray Gottesfeld MD and Dr Sue Sisley MD, plus a host of Australian clinicians experienced in this field. Attendance at the conference prior to the masterclass is strongly recommended for the required foundation knowledge for this masterclass.

The Masterclass has been designed to follow on from the one-day conference. It is therefore highly recommended that you attend the medicinal cannabis conference on the previous day so that you have the foundational knowledge for this Masterclass.

RACGP Category 2 CPD points approved


This Masterclass is open to Doctors, Nurses and Pharmacists (capped at 60 registrants)


Melbourne: Sunday 21 JULY 2019 VENUE: TBC


At the end of the conference and Masterclass, attendees should be able to:

  1. Safely prescribe a range of medicinal cannabis products for a range of mental health disorders and chronic pain.
  2. Provide a rationale for the use of medicinal cannabis in the treatment of a range of mental health disorders and co-morbid chronic pain.
  3. Discuss the differences between THC and CBD in the treatment of mental health conditions.
  4. Complete an SAS-B and Authorised Prescriber application under the TGA Special Access Scheme and Authorised Prescriber Scheme.
  5. Source information about potential drug-cannabis interactions and communicate clearly to patients about the safety aspects of medicinal cannabis.
Chief Executive Officer
Global Health Initiative (GHI) Foundation


    The Masterclass has been approved by the RACGP for Category 1 CPD points. CPD points may also be applicable to other professional bodies. Please contact your professional association for further information. Click below for information about RACGP CPD requirements.


    Topic Speaker
    8.15am-9.00am Registration


    Professor Ian Brighthope, Founder ACNEM
    9.05am-9.10am Setting the Scene MC: Prof Kylie O’Brien
    9.10am-9.30am General treatment considerations when treating mental health conditions with medicinal cannabis: actions of CBD, THC, Terpenes Dr. Sue Sisley MD US

    CBD only versus CBD plus THC: When to Prescribe What

    Dr. Ray Gottesfeld MD, US

    Case Study 1 Anxiety

    Group Work

    Facilitators: Sue Sisley, Teresa Towpik, Sinclair Bode, Justin Sinclair, Gull Herzberg, Dr. Karen Hitchcock
    10.30am-11.00am BREAK
    11.00am-11.30am Discussion of Case Study 1 Anxiety Panel


    Case Study 2 PTSD

    Group Work

    Facilitators: Sue Sisley, Teresa Towpik, Sinclair Bode, Justin Sinclair, Gull Herzberg, Dr. Karen Hitchcock
    12.30am-1.00pm Discussion of Case Study 2 PTSD Panel
    1.00pm-2.00pm LUNCH
    2.00pm-3.00pm Regulations for Prescribing: Applying through the SAS-B and AP Schemes (Group Work) Prof Kylie O’Brien and Facilitators
    3.00pm-3.30pm Case Study 3 Insomnia Facilitators: Dr. Sue Sisley MD, Dr. Ray Gottesfeld MD, Dr. Teresa Towpik, Dr. Sinclair Bode, Mr Justin Sinclair, Dr. Gull Herzberg, Dr. Karen Hitchcock
    3.30pm-4.00pm Discussion of Case Study 3 Insomnia Panel



    Case Study 4 Chronic Pain and Co-Morbid Depression

    (Group Work)

    Facilitators: Sue Sisley, Teresa Towpik, Sinclair Bode, Justin Sinclair, Gull Herzberg, Dr. Karen Hitchcock
    4.50pm-5.20pm Discussion of Case Study 4 Chronic Pain and Co-Morbid Depression Panel
    5.20pm-5.40pm Future considerations in Cannabis Medicine – a clinical perspective Dr. Ray Gottesfeld MD
    5.45pm CLOSE

    Note: GHI (Aus) Ltd reserves the right to make changes to the conference and Masterclass programs, including speakers, where necessary.


    View Sponsor Bio

    Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. The Company’s main initiatives are to advance research on medicinial cannabis and and manufacture cannabis-based products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. The Company is working with developing nations on integrative programs to improve affordable healthcare and creating industry.  

    View Sponsor Bio

    VIVO Cannabis’ Beacon Medical brand offers pharmaceutical-grade products grown in small batches at our state-of-the-art facility in Napanee, Ontario. Beacon Medical turns these plants into a variety of Cannabis products for patients to treat their disease. Our focus and pharmaceutical heritage mean that we implicitly understand the needs of prescribing physicians and their patients; and we provide a unique and simplified approach to navigating medical cannabis using the Beacon Cannatypes™ classification system. Beacon Medical is committed to the education of the community and health- care professionals who are interested in learning about Medicinal Cannabis;
    and to ensuring that Australian patients have access to safe cannabis medicines.

    View Sponsor Bio

    Tilray is a global leader in medical cannabis ciltivation, production and research, offering a range of cannabinoid products to patients. pharmaicies and researchers in the European Union, Australia, Canada and the Americas.  

    View Sponsor Bio

    Entoura is an Australian operated healthcare company, developing and supplying high quality medicinal cannabis products. Established by Professor Ian Brighthope, who over 40 years ago founded Nutrition Care Pharmaceuticals, one of Australia’s exclusive companies in its ability to both formulate and manufacture therapeutic nutraceutical medicines. Entoura is committed to the development of high-quality innovative therapeutics that are supported by outstanding research programs, validated with clinical evidence and disseminated via exceptional education programs. Entoura is active in the Medicinal Cannabis industry, supporting medicinal cannabis research, education, manufacturing and patient access. Our vision is to open new pathways for previously inaccessible practitioner – patient treatment intervention.

    View Sponsor Bio

    Medlab Clinical is an Australian medical research organisation that formulates innovative solutions to provide the best integrative patient care. We are your partners in providing evidence-based nutraceuticals and pharmaceuticals reinforced by clinical trials and laboratory research.

    Medlab showcases the latest innovative adjunctive medicines designed to improve patients’ quality of life. Among several clinical trials we are currently conducting, notable conditions we aspire to influence via our patented probiotic formulations are Depression and Type-2 Diabetes. We are also pioneering pivotal research utilising Medicinal Cannabis via our NanoCelleä technology in Advanced Cancer Pain and Chemotherapy-Induced Nausea and Vomiting and Seizures.

    View Sponsor Bio

    Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH).

    Althea aims to supply pharmaceutical grade medicinal cannabis products to help improve the lives of patients suffering from debilitating conditions.

    Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.